The Needlestick
Crisis

According to the Centers for Disease Control and Prevention (CDC), approximately 385,000 needlestick and sharps-related injuries occur annually among healthcare workers in the United States alone. The A historical NIOSH estimate places 5.6 million U.S. healthcare and related workers at risk of occupational exposure to bloodborne pathogens through these injuries.

The consequences are devastating. A single needlestick can transmit HIV, Hepatitis B, or Hepatitis C — diseases that alter or end lives. Nurses, surgeons, lab technicians, and custodial staff face this risk every shift. The injuries occur most frequently in patient rooms, during procedures, and when disposing of used sharps.

Yet the CDC's own research confirms that 62 to 88 percent of sharps injuries can be prevented simply by using safer medical devices. The technology existed. The question was never whether it worked — but whether corporations would allow it to reach the workers who needed it.

In the early 1990s, Texas inventor Thomas Shaw developed the VanishPoint — a retractable syringe that automatically retracts the needle into the barrel after injection, making reuse or accidental needlestick physically impossible. His company, Retractable Technologies, Inc. (RTI), received NIH funding and FDA approval for the device.

The VanishPoint worked. Clinical studies confirmed it eliminated needlestick injuries in facilities that adopted it. The device was cost-competitive with conventional syringes. Hospitals that tested it reported zero sharps injuries from retractable devices. The solution existed — engineered, tested, approved, and ready.

But the device couldn't reach the hospitals that needed it. Not because of any flaw in the technology — but because of a system designed to protect market share over worker safety.

Group Purchasing Organizations (GPOs) — intermediaries that negotiate bulk contracts between manufacturers and hospitals — held exclusive agreements with Becton Dickinson, the dominant syringe manufacturer. These contracts effectively locked out competitors, regardless of whether their products were safer or cheaper.

The GPOs received administrative fees from manufacturers — creating a perverse incentive to maintain exclusivity with the largest suppliers rather than allow competition from innovative safety devices. Hospitals that wanted to purchase VanishPoint syringes were told they would lose their GPO pricing on all other supplies if they broke the exclusive contract.

This pattern — corporations prioritizing profit over worker safety — is not unique to the medical supply industry. For decades, asbestos manufacturers knew their products caused mesothelioma and lung disease, yet continued exposing workers across hundreds of occupations. The mechanism differs; the calculus is identical: profit over people.

In 1998, Houston attorneys Mike Weiss and Paul Danziger filed a federal antitrust lawsuit on behalf of Retractable Technologies against Becton Dickinson and the GPOs. The case alleged that exclusive dealing arrangements violated antitrust law by blocking safer products from reaching the market.

It was a David-versus-Goliath fight. Two attorneys from a small Houston firm took on a major medical-supply corporation with extensive legal resources. Mike Weiss, brilliant and relentless, drove the case forward with obsessive energy — filing motions, deposing executives, building the antitrust theory that would eventually prevail.

Weiss died of a drug overdose on October 2, 1999, at age 32 — before the case went to trial. Paul Danziger continued the fight. The case ultimately settled for $100 million in 2004. The federal Needlestick Safety and Prevention Act had already become law in 2000 amid a broader national response to occupational sharps injuries and safer-device technology.

This is the story told in the 2011 film Puncture, starring Chris Evans as Mike Weiss and executive produced by Paul Danziger. Read the full behind-the-scenes story →

On November 6, 2000, President Clinton signed the Needlestick Safety and Prevention Act (HR.5178) into law. The legislation amended OSHA's Bloodborne Pathogens Standard to require employers to:

• ▸Use safety-engineered sharps devices wherever clinically appropriate
• ▸Maintain detailed sharps injury logs documenting each incident
• ▸Solicit frontline employee input in selecting safety devices
• ▸Evaluate and adopt new safety technologies as they become available

The regulations took effect on April 18, 2001. In the years following, hospitals across the country adopted retractable syringes and other safety-engineered devices. Needlestick injuries declined significantly — proving that the technology worked, and that only corporate obstruction had prevented its adoption.

Retractable Technologies’ market-access dispute ran alongside the broader national debate over safer needle technology. The public legislative record identifies occupational sharps injuries, safer-device developments, OSHA materials, and congressional consideration as the bases for the Act; it does not identify the litigation as a cause or drafting source.

The needlestick crisis follows a pattern repeated across industries: corporations with knowledge of harm choosing profit over protection. The same calculus that kept safety needles out of hospitals for a decade kept asbestos in workplaces for half a century.

Asbestos manufacturers knew as early as the 1930s that their products caused fatal lung disease. By the 1960s, the link to mesothelioma — a rare and aggressive cancer of the lung lining — was established in medical literature. Yet workers in hundreds of occupations continued to be exposed without warning or protection — shipyard workers, construction crews, power plant operators, automotive mechanics, and military personnel among them.

In both cases, the path to justice required the same elements: tenacious attorneys willing to take on powerful corporations, litigation that built an evidentiary record of corporate knowledge, and ultimately legislative or regulatory action that forced industry-wide change.

The fight that inspired Puncture didn't end with safety needles. Paul Danziger — the attorney who stood beside Mike Weiss in the original case — continues that same fight today as founding partner of Danziger & De Llano, LLP, representing families affected by mesothelioma and asbestos-related diseases nationwide.